Evidence map›Paper›PMID 34463844›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2022

A novel mutation in collagen gene COL1A2 associated with transient regional osteoporosis.

M Varenna, C Crotti, M T Bonati, F Zucchi, M Gallazzi, R Caporali

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Neridronate for transient osteoporosis of the hip in a child.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

M VarennaBone Diseases Unit, Department of Rheumatology, Gaetano Pini Institute, Via Pini, 9, 20122, Milan, Italy. massimo.varenna@asst-pini-cto.it.ORCID http://orcid.org/0000-0002-8644-0909
C CrottiBone Diseases Unit, Department of Rheumatology, Gaetano Pini Institute, Via Pini, 9, 20122, Milan, Italy.
M T BonatiClinic of Medical Genetics, IRCCS Istituto Auxologico Italiano, Milan, Italy.
F ZucchiBone Diseases Unit, Department of Rheumatology, Gaetano Pini Institute, Via Pini, 9, 20122, Milan, Italy.
M GallazziDepartment of Radiology, Gaetano Pini Institute, Milan, Italy.
R CaporaliBone Diseases Unit, Department of Rheumatology, Gaetano Pini Institute, Via Pini, 9, 20122, Milan, Italy.
Istituto Ortopedico Gaetano Pini · ITIRCCS Istituto Auxologico Italiano · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A young man was diagnosed with transient regional osteoporosis (TRO). The genetic analysis revealed a novel de novo likely pathogenic variant in COL1A2 gene. Our hypothesis is that TRO may be a possible clinical manifestation of osteogenesis imperfecta due to a reduced bone mass and an impaired trabecular mechanical competence.

introductionTransient regional osteoporosis (TRO) is a disease characterized by episodes of pain in the lower limbs involving the hip, knee, ankle or foot. Here, we present a clinical case of a Caucasian 25-year-old man exhibiting TRO. Based on few mild clinical findings suggestive of osteogenesis imperfecta (OI), but without a history of fragility fractures, we performed a genetic assessment to investigate this hypothesis.

methodsMedical history was obtained from the patient and family members, including biochemical, RMI and DXA assessments. Next-generation sequencing of COL1A1, COL1A2, COL2A1, CASR, CYP19A1, CUL7, CRTAP, KAL1, LEPRE1, LRP5, PPIB and SLC9A3R1, genes involved in juvenile osteoporosis, was performed.

resultsWe identified a novel de novo heterozygous missense variant, c.488G > A, in exon 11 of the COL1A2 gene (NM_000089.3), resulting in the putative p.Gly163Asp substitution in the N-terminal part of the helical domain of type I collagen. The variant was predicted to be damaging by the in silico prediction tools and the mutation was therefore classified as likely pathogenic. This mutation can affect skeletal health impairing bone mass and trabecular mechanical competence, inducing a disease whose features strictly evoke a TRO.

conclusionThe present study describes a novel de novo heterozygous missense variant in COL1A2 gene, possibly inducing a propensity to trabecular microfractures. The recurrent symptomatic bone marrow oedema episodes could be the clinical picture consistent with the hypothesis of an inherited connective tissue disorder giving bone fragility.

Indexed as

Osteogenesis ImperfectaOsteoporosisAdultCollagen Type ICollagen Type I, alpha 1 ChainHumansMaleMutationCOL1A2 protein, humanCollagen Type ICollagen Type I, alpha 1 ChainCollagen Type I, alpha2 SubunitBone marrow oedemaCollagen defectsOsteogenesis imperfectaTransient regional osteoporosis

Identifiers

PMID34463844
OpenAlexW3198344959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.